These agents, particularly FAP inhibitors (FAPIs), allow for non-invasive imaging that can complement existing modalities like [18F]FDG PET, offering high specificity and sensitivity in certain cancer types, revealing tumors that might otherwise go undetected [5]. This evidence concerns the gene FAP and cancer.